	US 12,214,088 B2
	Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive
Marco Emgenbroich, Rheinbach (DE); Eva-Marie Prinz, Weissenthurm (DE); Elke Klein, Bad Neuenahr-Ahrweiler (DE); Heike Kluth, Ochtendung (DE); Xavier Thomas, Famars (FR); and Linda Sue Nartker, Midland, MI (US)
Assigned to LTS LOHMANN THERAPIE-SYSTEME AG, Andernach (DE); and DDP SPECIALTY ELECTRONIC MATERIALS US 9, LLC, Wilmington, DE (US)
Appl. No. 16/755,049
Filed by LTS LOHMANN THERAPIE-SYSTEME AG, Andernach (DE); and DDP Specialty Electronic Materials US 9, LLC, Wilmington, DE (US)
PCT Filed Oct. 11, 2018, PCT No. PCT/EP2018/077792 § 371(c)(1), (2) Date Apr. 9, 2020, PCT Pub. No. WO2019/072998, PCT Pub. Date Apr. 18, 2019.
Claims priority of provisional application 62/570,745, filed on Oct. 11, 2017.
Claims priority of application No. 17205546 (EP), filed on Dec. 5, 2017.
Prior Publication US 2020/0397715 A1, Dec. 24, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/70 (2006.01); A61K 31/165 (2006.01); A61K 47/08 (2006.01); A61K 47/10 (2017.01); A61K 47/32 (2006.01); A61P 9/12 (2006.01); A61P 25/00 (2006.01)

CPC A61K 9/7084 (2013.01) [A61K 9/7069 (2013.01); A61K 31/165 (2013.01); A61K 47/08 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01)]

10 Claims

1. A transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising:

A) a backing layer; and

B) a guanfacine-containing layer;

wherein the transdermal therapeutic system comprises at least one polymer and a combination of a dispersing agent, a permeation enhancer, and a solubilizer;

wherein the dispersing agent is a polyethylene glycol C₈-C₂₀-alkyl ether having from 2 to 10 EO units, the permeation enhancer is oleyl alcohol, and the solubilizer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.